Ayala Pharmaceuticals Inc. (AYLA) is a Specialty Chemicals company listed on NASDAQ. There were no new wire items for AYLA in the last 30 days. The most recent was published Nov 1, 2023.
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Martell Bridget A3 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 3 filed by new insider Orbach Pini3 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 3 filed by new insider Golan Roy3 - Old Ayala, Inc (0001797336) (Issuer)
- SECSEC Form 10-K filed by Ayala Pharmaceuticals Inc.10-K - Old Ayala, Inc (0001797336) (Filer)
- 13D/GSEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
- 13D/GSEC Form SC 13G filed by Ayala Pharmaceuticals Inc.SC 13G - Old Ayala, Inc (0001797336) (Subject)
- 13D/GSEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
- SECSEC Form 15-12G filed by Ayala Pharmaceuticals Inc.15-12G - Old Ayala, Inc (0001797336) (Filer)
- SECAyala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets8-K - Old Ayala, Inc (0001797336) (Filer)
- INSIDERSEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company4 - Old Ayala, Inc (0001797336) (Issuer)
- SECSEC Form EFFECT filed by Ayala Pharmaceuticals Inc.EFFECT - Old Ayala, Inc (0001797336) (Filer)
- SECSEC Form EFFECT filed by Ayala Pharmaceuticals Inc.EFFECT - Old Ayala, Inc (0001797336) (Filer)
- INSIDERSEC Form 4: Maimon Yossi returned 69,872 shares to the company, closing all direct ownership in the company4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4 filed by Spiegel Robert J.4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4: Sidransky David returned 250 shares to the company4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4: Mamluk Roni returned 265,345 shares to the company, closing all direct ownership in the company4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4 filed by Bisker-Leib Vered4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4 filed by Goldberg Murray A4 - Old Ayala, Inc (0001797336) (Issuer)
- INSIDERSEC Form 4: Gordon Gary B. returned 58,520 shares to the company, closing all direct ownership in the company4 - Old Ayala, Inc (0001797336) (Issuer)
- 13D/GSEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
- SECSEC Form POS AM filed by Ayala Pharmaceuticals Inc.POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
- SECSEC Form S-8 POS filed by Ayala Pharmaceuticals Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
- SECSEC Form POS AM filed by Ayala Pharmaceuticals Inc.POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
- SECSEC Form 25-NSE filed by Ayala Pharmaceuticals Inc.25-NSE - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
- PRAdvaxis and Ayala Pharmaceuticals Complete MergerREHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na
AYLA FAQ
8 questionsWhat does Ayala Pharmaceuticals Inc. do?
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for...What is the latest news on AYLA?
Quantisnow has not tracked any new filings, ratings or press releases for AYLA in the last 30 days. The most recent wire item was published on November 1, 2023.Where does AYLA stock trade?
Ayala Pharmaceuticals Inc. (AYLA) is listed on NASDAQ.What sector and industry is AYLA in?
Ayala Pharmaceuticals Inc. operates in the Consumer Discretionary sector, Specialty Chemicals industry.When did Ayala Pharmaceuticals Inc. go public?
Ayala Pharmaceuticals Inc. (AYLA) completed its IPO in 2020.What are analysts saying about AYLA?
Across the last 5 analyst actions on Ayala Pharmaceuticals Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Maxim Group: Buy with a $22.00 price target on 2021-12-20. Recent price targets range from $17.00 to $29.00.What companies are similar to AYLA?
Notable peers in the same industry include YHGJ (Yunhong Green CTI Ltd.), CSL (Carlisle Companies Incorporated), ASH (Ashland Inc.), NPT (Texxon Holding Limited), CLX (Clorox Company). Compare AYLA side-by-side with any of them on Quantisnow.How can I track AYLA on Quantisnow?
Quantisnow aggregates Ayala Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AYLA to receive live email and push alerts on every new disclosure.